Your Resource Center for Osteoporosis Education

Help your patients strengthen their bones

Mechanism of Disease

Globally, approximately 274 million women ≥ 50 years of age are expected to be at high risk of a fragility fracture by 2040.1 Learn more about the pathophysiology of osteoporosis, the pathways that regulate bone homeostasis, and how these pathways may contribute to osteoporosis.

Review this slide kit for an in-depth introduction to osteoporosis. Review this slide kit for an in-depth introduction to osteoporosis.

What is osteoporosis?

Learn about this skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue and how it contributes to fragility fractures.2

Role of sclerostin in postmenopausal osteoporosis

The basic science behind a fragility fracture is revealed here, with a specific focus on understanding the cellular mechanisms influencing bone formation. Sclerostin, a negative regulator of bone formation that inhibits WNT signaling, is introduced.

Advancing the understanding of postmenopausal osteoporosis: The role of the RANK ligand pathway in osteoclast-mediated bone loss

The RANK ligand pathway plays a key role in postmenopausal bone loss and osteoporosis. Watch the video to learn how declining estrogen levels following menopause affect RANK ligand expression and osteoclast-mediated bone resorption.

The science of bone remodeling

Take a visual journey through the interior of the bone to learn about bone anatomy and physiology. This video provides a unique opportunity to observe the cellular processes of bone formation and resorption.

Bone remodeling and modeling

Discover how the skeleton changes across the human lifespan. Learn about the dynamic process of bone remodeling and understand factors that lead to changes in bone mass.

The role of sclerostin in the regulation of bone mass and strength

See how sclerostin levels tend to increase with age and promote a reduction in bone mass and strength.7-9

Fragility fractures: Warning signs for osteoporosis10

1. Odén A, et al. Osteoporos Int. 2015;26:2243-2248. 2. International Osteoporosis Foundation. Accessed January 18, 2021. 3. Lin C, et al. J Bone Miner Res. 2009;24:1651-1661. 4. Li X, et al. J Biol Chem. 2005;280:19883-19887. 5. Kostenuik PJ. Curr Opin Pharmacol. 2005;5:618-625. 6. Eghbali-Fatourechi G, et al. J Clin Invest. 2003;111:1221-1230. 7. Ardawi MSM, et al. J Bone Miner Res. 2011;26:2812-2822. 8. Szulc P, et al. J Bone Miner Res. 2013;28:1760-1770. 9. Winkler DG, et al. EMBO J. 2003;22:6267-6276. 10. Camacho PM, et al. Endocr Pract. 2020;26(suppl 1):1-46.

These materials are provided for educational and non-commercial purposes only. All materials provided herein are licensed for use only under the Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International Public License linked here.